HIF-PH Inhibitors Archives

SEC Wades into Confusion Over FibroGen Safety Data in Anemia Drug

Astellas Pharma, AstraZeneca, Business, Clinical Trials, FDA/Regulatory, HIF-PH Inhibitors, Litigation, New Drug Applications, R&D, U.S. Securities and Exchange Commission (SEC)

According to a filing with the U.S. Security and Exchange Commission, FibroGen is tangled up in a Securities Class Action Litigation as well as Derivative Litigation regarding clinical trial data for the company’s drug Roxadustat, which is being developed with AstraZeneca and Astellas.

Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

Acquisitions, Anemia, Biotech, Business, Chronic Kidney Disease, Clinical Trials, Gene Therapy, HIF-PH Inhibitors, Oncology, Ophthalmics, People on the Move, Product Pipelines, Promotions, R&D

Tokyo-based Astellas Pharma announced that the company’s roxadustat met the primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease patients with anemia not on dialysis.

Japan’s Astellas looking for more deals to refuel drug pipeline

Allergies, Anemia, Bladder, Deals, Deals, DNA, Health, HIF-PH Inhibitors, Immunology, Japan, M&A, Patents, Prostate Cancer, R&D, Red Blood Cell, Therapeutics, Vaccines

Japan’s Astellas is seeking more deals to refill its drug pipeline as the pharmaceutical company created through a merger 10 years ago explores opportunities in both established and new therapy […]